Director Keith A. Meister of Illumina, Inc. (NASDAQ:ILMN) recently disclosed transactions involving a significant disposition of common stock. Specifically, Mr. Meister reported selling shares totaling approximately $47.9 million across May 13 and May 14, 2026. It is important to note that these sales were conducted through the indirect mechanism of investment funds.
On both May 13 and May 14, Mr. Meister utilized Corvex Management LP, which functions as an investment adviser for specific private investment funds (collectively termed the "Corvex Funds"), to sell a total of 329,460 shares of Illumina's common stock. These divestitures occurred at weighted average pricing levels that ranged between $144.13 and $148.14 per share. This activity took place while Illumina's stock was trading near the $165 mark, approaching its 52-week high valuation of $165.33, following a notable appreciation of 106% over the preceding year.
In addition to these sales, separate transactions related to the partial termination of equity swaps were reported on May 12, 2026. As part of this structured activity, the Corvex Funds acquired 255,378 shares of common stock at a cost of $102.82 per share. Concurrently, 255,378 shares were disposed of at a price of $144.66 per share. This disposition was associated with the cash settlement resulting from the termination of the swap agreement. The counterparty involved in the swap paid the Corvex Funds a total of $36,942,981.48, which represented the market price for the notional shares. From this amount, an offset of $26,257,965.96 was applied, representing the cost basis associated with those funds.
Following these detailed transactions, Mr. Meister's indirect beneficial ownership interest through the Corvex Funds is stated to be 3,500,048 shares of Illumina common stock. Furthermore, Mr. Meister maintains a direct holding of 4,566 shares. Regarding remaining equity swaps, which carry a cost basis of $102.82 per notional share, these are scheduled for termination on February 11, 2028. At that time, the Corvex Funds have the option to physically settle the transaction for 24,562 shares.
Beyond the director's activities, recent operational and financial disclosures provide context regarding Illumina's market standing. For the last twelve months, as of Q1 2026, the genomics company reported robust revenue amounting to $4.39 billion, alongside a gross profit margin that stood at 68%. Furthermore, in a separate news development, Illumina Inc. announced stronger-than-expected earnings for its first quarter of 2026. The company achieved a non-GAAP earnings per share (EPS) of $1.15, which surpassed the analyst forecast of $1.06. Revenue for the quarter reached $1.09 billion, exceeding expectations by an amount of $20 million.
These strong quarterly results prompted varied responses from major financial institutions. Evercore ISI reacted to the earnings data by increasing its price target for Illumina shares. The firm raised its target from $150 to $155 while maintaining an Outperform rating, citing both the robust quarterly performance and significant clinical growth observed within the company. In contrast, Canaccord lowered its price target on Illumina to $140 from $150, while maintaining a Hold rating. This adjustment was attributed to concerns regarding increased competition specifically within the high-throughput sequencing sector. Meanwhile, RBC Capital initiated coverage of Illumina with an Outperform rating and set a price target of $170, emphasizing the company's growing clinical momentum and noting that competitive risks had diminished.
The confluence of these events presents several key takeaways for market observers.
Risks
More from Insider Trading